HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Raloxifene Hydrochloride (Evista)

A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.
Also Known As:
Evista; Keoxifene; Keoxifene Hydrochloride; LY 139481; LY 156758; LY-139481; LY-156758; Raloxifene HCl; LY139481; LY156758; Raloxifene
Networked: 1812 relevant articles (196 outcomes, 545 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1. Jordan, V Craig: 41 articles (11/2021 - 01/2002)
2. Vogel, Victor G: 29 articles (01/2014 - 06/2002)
3. Costantino, Joseph P: 17 articles (01/2014 - 06/2002)
4. Wickerham, D Lawrence: 16 articles (01/2015 - 06/2002)
5. Ohta, Hiroaki: 15 articles (07/2021 - 01/2004)
6. Wolmark, Norman: 14 articles (01/2015 - 06/2002)
7. Cummings, Steven R: 14 articles (06/2011 - 01/2002)
8. Jordan, V C: 14 articles (01/2007 - 01/2000)
9. Cauley, Jane A: 13 articles (11/2012 - 01/2002)
10. Barrett-Connor, Elizabeth: 13 articles (08/2009 - 12/2002)

Related Diseases

1. Breast Neoplasms (Breast Cancer)
2. Osteoporosis
3. Schizophrenia (Dementia Praecox)
4. Postmenopausal Osteoporosis
5. Neoplasms (Cancer)

Related Drugs and Biologics

1. Tamoxifen
2. Selective Estrogen Receptor Modulators (SERM)
3. Estrogens (Estrogen)
4. Alendronate (Alendronate Sodium)
5. Raloxifene Hydrochloride (Evista)
6. Estradiol (Delestrogen)
7. Antipsychotic Agents (Antipsychotics)
8. Risedronic Acid (Actonel)
9. bazedoxifene
10. Estrogen Receptors

Related Therapies and Procedures

1. Therapeutics
2. Chemoprevention
3. Hysterectomy
4. Drug Therapy (Chemotherapy)
5. Estrogen Replacement Therapy